iBio, Inc. 8-K/A

What Happened

• iBio, Inc. filed Amendment No. 1 to its Form 8-K (original filed April 8, 2026) on April 17, 2026 to correct a typographical error about the expiration of its Series G warrants. The amendment states the Series G Warrants will expire at 5:00 p.m. (New York City time) on May 20, 2026. The Series G Warrants relate to the right to purchase up to 35,770,000 shares of the company’s common stock.

Key Details

• Amendment No. 1 filed April 17, 2026 corrects the expiration to 5:00 p.m. (NYC) on May 20, 2026.
• The Series G Warrants are exercisable to purchase up to 35,770,000 shares of common stock.
• The amendment updates the number of outstanding Series G Warrants and the company’s outstanding common stock count.
• The filing adds disclosure that exercises of Series G Warrants may result in issuance of pre-funded warrants.

Why It Matters

• The corrected expiration date and updated counts are material for investors tracking potential near-term dilution: warrant exercises could increase the share count or convert into pre-funded warrants that affect outstanding shares and ownership percentages.
• Accurate timing and share/warrant counts help investors assess the potential impact on voting power and per-share metrics; because the expiration is May 20, 2026, investors should note the short window for potential exercises or related transactions.